COMP <GO>
NVO vs UNH // REVENUE GROWTH (YOY)
Novo Nordisk A/S (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: NVO 5
— UNH 9
▲ REVENUE GROWTH (YOY) LEADER: UNH
LAST: $40.00 (+2.20%) • MKT CAP: $173.31B
revenue-growth
2.20%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
revenue-growth
6.46%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVO VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NVO | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 11.47% | -1.57 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 16.4x | +4.55 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 6.48% | -4.27 | UNH | /fcf-yield <GO> |
| Operating Margin | 13.90% | 4.82% | +9.08 | NVO | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 3.14% | +7.76 | NVO | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 2.20% | 6.46% | -4.26 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 3.12 | +0.62 | NVO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.74% | -0.24 | NVO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.9 | 56.0 | -2.15 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.33 | +0.54 | NVO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.5x | 17.1x | +13.41 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $173.31B | $364.66B | -$191.35B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NVO REV | UNH REV | NVO GROSS % | UNH GROSS % | NVO FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $447.57B | — | 88.7% | — | $16.07B |
| FY 2024 | — | $400.28B | — | 88.3% | — | $20.70B |
| FY 2023 | — | $371.62B | — | 89.6% | — | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVO // BETA 0.87
UNH // BETA 0.33